VivoSeq
Oncology

Nasopharyngeal Cancer

1

Pipeline Programs↗

9

Active Trials↗

3

Companies Involved↗

Nasopharyngeal Cancer is an early-stage landscape with 1 program across 3 companies. The most active players are Cullinan Therapeutics Inc., Radiation Therapy Oncology Group, Biotech Pharmaceutical Co., Ltd..

Intelligence

Pipeline Metrics

Competitive Density

28/100

Pipeline Velocity

6/100

Mech. Concentration

N/A

Completion Rate

93/100

Attrition Rate

3/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

C

Cullinan Therapeutics Inc.

1 program

Phase 2Radiation Therapy Oncology Group logo

Radiation Therapy Oncology Group

0 programs

PreclinicalB

Biotech Pharmaceutical Co., Ltd.

0 programs

Preclinical

Pipeline

Programs by Phase

Preclinical
No programs
Phase 1
No programs
Phase 21

VK-2019

Cullinan Therapeutics Inc.

Phase 3
No programs
Approved
No programs

Analysis

Trial Status

30

clinical trials

Completed13 · 43%
Unknown status7 · 23%
Recruiting4 · 13%
Active, not recruiting3 · 10%
Not yet recruiting2 · 7%
Withdrawn1 · 3%

Clinical Trials

Trial Activity

30 trials

Testing Nivolumab and Ipilimumab Immunotherapy With or Without the Targeted Drug Cabozantinib in Recurrent, Metastatic, or Incurable Nasopharyngeal Cancer
Recruiting·National Cancer Institute (NCI)·Phase 2·NCT05904080·50 enrolled
Randomised Trial of Induction Gemcitabine and Cisplatin Versus Gemcitabine, Cisplatin, Pembrolizumab and Bevacizumab (GPPB) in Nasopharyngeal Cancer
Recruiting·NNational University Hospital, Singapore·Phase 2·NCT05305131·50 enrolled
Pembrolizumab and Olaparib in Recurrent/Metastatic, Platinum Resistant Nasopharyngeal Cancer
Recruiting·GGruppo Oncologico del Nord-Ovest·Phase 2·NCT04825990·30 enrolled
Nivolumab in Nasopharyngeal Cancer With Progression During or After Platinum-based Treatment
Recruiting·MMaria Sklodowska-Curie National Research Institute of Oncology·Phase 2·NCT04875611·32 enrolled
NEO-SPACE Trial: Pembrolizumab and Chemoradiation in Nasopharyngeal Cancer
Active, not recruiting·—·Phase 2·NCT03734809·43 enrolled
Autologous Dendritic Cells and Allogenic Dendritic Secretomes for Patients With Advanced Nasopharyngeal Cancer
Active, not recruiting·PPT. Prodia Stem Cell Indonesia·Phase 1/2·NCT05261750·15 enrolled
Phase 2, Open-label, Clinical Trial of a Novel Small Molecule EBNA1 Inhibitor, VK 2019, in Patients With Epstein Barr Virus Positive Nasopharyngeal Cancer (NPC) and Other EBV-associated Cancers, With Pharmacokinetic and Pharmacodynamic Correlative Studies
Active, not recruiting·SStanford University·Phase 2·NCT04925544·13 enrolled
JMT101 Combined With Mitoxantrone Liposome for Nasopharyngeal Cancer
Not yet recruiting·SShanghai JMT-Bio Inc.·Phase 2·NCT06892431·150 enrolled
Integrating Allogeneic NK Cells in High-risk Advanced Stage III-IV Nasopharyngeal Cancer Patients
Not yet recruiting·SSingapore General Hospital·Phase 1/2·NCT07247201·31 enrolled
Efficacy of Recombinant Epstein-Barr Virus (EBV) Vaccine in Patients With Nasopharyngeal Cancer Who Had Residual EBV DNA Load After Conventional Therapy
Completed·—·Phase 2·NCT01094405·25 enrolled
T-Lymphocytes in Treating Patients With Epstein-Barr Virus-Positive Nasopharyngeal Cancer, NPC
Completed·—·Phase 1·NCT00609219·25 enrolled
To Evaluate the Efficacy of ZOMETA® in Treatment of Bone Metastases in Patients With Stage IV Nasopharyngeal Cancer
Completed·SSun Yat-sen University·Phase 2·NCT00697619·60 enrolled
Radiation Therapy With or Without Chemotherapy in Reducing Mouth Dryness in Patients With Nasopharyngeal Cancer
Completed·Radiation Therapy Oncology Group logoRadiation Therapy Oncology Group·Phase 2·NCT00057785·68 enrolled
Pazopanib Hydrochloride in Treating Patients With Stage IV or Recurrent Nasopharyngeal Cancer
Completed·National Cancer Institute (NCI)·Phase 2·NCT00454142·33 enrolled
New Approach of Assessing Drug Response for Treatment of Nasopharyngeal Cancer
Completed·—·N/A·NCT01365208·70 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)